Homepage>Company>Media>Company news>2017>NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Platinum-Resistant Ovarian Cancer
NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Platinum-Resistant Ovarian Cancer